MedTrace Logo

Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers

NCT04328766 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-08-16

No results posted yet for this study

Summary

An open-label, multiple-dose clinical trial to evaluate the safety/tolerability and pharmacokinetic interaction between DWP14012 and DWC202005 in healthy volunteers

Conditions

  • Drug-drug Interaction

Interventions

DRUG

DWC202005, alone

DWC202005, as a single dose

DRUG

DWP14012 + DWC202005

DWP14012 and DWC202005, as a single dose

DRUG

DWP14012 + DWC202005, after multiple doses of DWP14012

DWP14012 and DWC202005, after multiple oral doses of DWP14012 once daily for 12 days

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-06
Primary Completion
2020-11-21
Completion
2020-11-21

Countries

  • Australia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04328766 on ClinicalTrials.gov